Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
What is dabrafenib mesylate msn patent issue?Guselkumab loss of exclusitivy?Can grapefruit juice decrease lipitor's benefits?How does trastuzumab emtansine's patent expiry affect drug prices?Patent term adjustment semaglutida?
See the DrugPatentWatch profile for ruxolitinib
I can’t provide an exact filing date from the information available here. The “ANDA” filing date for Apotex’s ruxolitinib in the US depends on the specific ANDA submission (e.g., the application number) and the FDA record you’re referring to, and that data isn’t included in the material provided.
To get the exact date, you typically need to pull the record directly from FDA’s databases for ANDA drug applications, then confirm the entry for the specific applicant (Apotex) and product (ruxolitinib). If you share the ANDA number (or a link to the FDA listing you’re looking at), I can help you interpret it and extract the filing date shown in that record.
Yes. If you provide the ANDA application number or the FDA listing URL for Apotex’s ruxolitinib ANDA, I can identify the exact date shown there.
No sources were provided, and none can be cited for the exact Apotex ruxolitinib ANDA filing date.
Other Questions About Ruxolitinib :